EC OKs Adcetris for CD30-positive cutaneous T-cell lymphoma
The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Read More





